$7.67
1.03% yesterday
Nasdaq, Apr 16, 10:00 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Stock price

$7.67
-0.73 8.69% 1M
+0.49 6.82% 6M
-1.31 14.59% YTD
+2.67 53.40% 1Y
-3.63 32.12% 3Y
-7.85 50.58% 5Y
+3.50 83.93% 10Y
Nasdaq, Closing price Wed, Apr 16 2025
-0.08 1.03%
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Key metrics

Market capitalization $1.06b
Enterprise Value $785.27m
P/E (TTM) P/E ratio 200.78
EV/FCF (TTM) EV/FCF 18.17
EV/Sales (TTM) EV/Sales 3.34
P/S ratio (TTM) P/S ratio 4.53
P/B ratio (TTM) P/B ratio 2.89
Revenue growth (TTM) Revenue growth 33.97%
Revenue (TTM) Revenue $235.13m
EBIT (operating result TTM) EBIT $14.07m
Free Cash Flow (TTM) Free Cash Flow $43.21m
Cash position $358.48m
EPS (TTM) EPS $0.04
P/E forward 15.05
P/S forward 4.12
EV/Sales forward 3.04
Short interest 8.42%
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
83%
Hold
17%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
235 235
34% 34%
100%
- Direct Costs 28 28
90% 90%
12%
207 207
29% 29%
88%
- Selling and Administrative Expenses 153 153
16% 16%
65%
- Research and Development Expense 21 21
58% 58%
9%
34 34
147% 147%
14%
- Depreciation and Amortization 19 19
64% 64%
8%
EBIT (Operating Income) EBIT 14 14
117% 117%
6%
Net Profit 5.75 5.75
107% 107%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Neutral
24/7 Wall Street
about one month ago
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Neutral
Seeking Alpha
about 2 months ago
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications and Investor Relations Peter Greenleaf - President, Chief Executive Officer and Director Joe Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Vishwesh Shah - TD Cowen Ol...
Neutral
Business Wire
about 2 months ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 130
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today